ACM
ACAD icon

AlphaCrest Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

AlphaCrest Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-35,044
Closed -$573K – 13
2022
Q3 		$573K Buy
35,044
+24,258
+225% +$393K 0.03% 918
2022
Q2 		$152K Sell
10,786
-40,760
-79% -$761K 0.01% 1220
2022
Q1 		$1.25M Buy
51,546
+34,143
+196% +$826K 0.07% 445
2021
Q4 		$406K Sell
17,403
-49,276
-74% -$991K 0.02% 1168
2021
Q3 		$1.11M Buy
66,679
+11,874
+22% +$229K 0.06% 569
2021
Q2 		$1.34M Buy
54,805
+13,601
+33% +$307K 0.06% 524
2021
Q1 		$1.06M Buy
41,204
+31,960
+346% +$1.41M 0.06% 474
2020
Q4 		$494K Buy
+9,244
New +$459K 0.04% 657
2020
Q3 		– Sell
-6,233
Closed -$302K – 1076
2020
Q2 		$302K Sell
6,233
-16,838
-73% -$808K 0.05% 625
2020
Q1 		$975K Buy
23,071
+12,430
+117% +$512K 0.12% 287
2019
Q4 		$455K Buy
10,641
+2,945
+38% +$128K 0.04% 846
2019
Q3 		$277K Buy
+7,696
New +$233K 0.02% 1118

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

AlphaCrest Capital Management's ACAD Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2022, closing a stake of 35,044 shares — an estimated $573K sold.

AlphaCrest Capital Management first reported a position in ACAD in Q3 2019 and held it in 12 quarters. The position peaked at $1.34M in Q2 2021. 228 funds tracked by Wall St. Rank hold ACAD as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 35,044 Acadia Pharmaceuticals shares in Q4 2022, an estimated $573K.
  • AlphaCrest Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 12 quarters.
  • AlphaCrest Capital Management's Acadia Pharmaceuticals position peaked at $1.34M in Q2 2021.
  • 228 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.